Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.
It is known that estramustine (EM) accumulates in cells at the G2/M-phase and causes metaphase arrest of various cell types. The inhibitory effect is mediated by interaction with microtubule-associated proteins (MAPs) and/or tubulin. Estramustine-binding protein (EMBP) is a secretory protein which has been found in a number of different tumor cells and has been shown to faciliate the uptake of EM into cells. In this study the efficacy of EM in arresting cells at metaphase was studied, using four different human cell lines; the prostatic cancer cell line DU 145, the breast cancer cell line MDA 231, the colon cancer cell line Colon 320, and the urinary bladder cancer cell line RT4. The cells were incubated with EM at a concentration of 10 micrograms/ml for 24 hours. The data reveal an increase in metaphase arrests in the DU 145 and in Colon 320 cell lines. Both of these cell lines were found to contain high amounts of EMBP using a dot-blot assay. The other two cell lines, MDA 231 and RT4 had undetectable intracellular amounts of the protein and exhibited a low increase in metaphase arrests. The cell lines were analysed regarding S-phase fraction with flow-cytometry (FCM) to exclude the growth rate of the cells as a limiting factor. The results from the FCM confirmed the cytogenic analysis, that is a higher percentage of cells were in the G2/M phase in both the DU 145 and Colon 320 cell line compared to MDA 231 and RT4. EM causes mitotic arrest in those cell lines that contain detectable amounts of EMBP.
Eklöv
S
S
Department of Oncology, University Hospital, Uppsala, Sweden.
Mahdy
E
E
Wester
K
K
Björk
P
P
Malmström
P U
PU
Busch
C
C
Nilsson
S
S
D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000494:pharmacology*; D001943:Breast Neoplasms; D002352:Carrier Proteins / Q000378:metabolism*; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division; D002460:Cell Line; D003110:Colonic Neoplasms; D004961:Estramustine / Q000378:metabolism* / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007700:Kinetics; D008297:Male; D008677:Metaphase / Q000187:drug effects; D011471:Prostatic Neoplasms; D029584:Prostatic Secretory Proteins; D016196:S Phase; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms
D018931:Antineoplastic Agents, Hormonal; D002352:Carrier Proteins; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D004961:Estramustine